• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Preclinical research progress in HER2-targeted small-molecule probes for breast cancer.针对乳腺癌的 HER2 靶向小分子探针的临床前研究进展。
Radiologie (Heidelb). 2024 Nov;64(Suppl 1):47-53. doi: 10.1007/s00117-024-01338-5. Epub 2024 Jul 22.
2
Current Progress in Human Epidermal Growth Factor Receptor 2 Targeted Therapies in Esophagogastric Cancer.食管癌和胃癌中人类表皮生长因子受体2靶向治疗的当前进展
Surg Oncol Clin N Am. 2017 Apr;26(2):313-324. doi: 10.1016/j.soc.2016.10.005. Epub 2017 Feb 10.
3
Development of the Tumor-Specific Antigen-Derived Synthetic Peptides as Potential Candidates for Targeting Breast and Other Possible Human Carcinomas.肿瘤特异性抗原衍生合成肽作为靶向乳腺癌和其他可能人类癌的潜在候选物的开发。
Molecules. 2019 Aug 29;24(17):3142. doi: 10.3390/molecules24173142.
4
Targeting HER2 in Advanced Breast Cancer.针对晚期乳腺癌中的人表皮生长因子受体2（HER2）
Methods Mol Biol. 2017;1652:63-77. doi: 10.1007/978-1-4939-7219-7_4.
5
[Her2 a paradigm for targeted therapy].[人表皮生长因子受体2：靶向治疗的范例]
Bull Cancer. 2011 Oct;98(9):1011-7. doi: 10.1684/bdc.2011.1379.
6
Review: Radionuclide Molecular Imaging Targeting HER2 in Breast Cancer with a Focus on Molecular Probes into Clinical Trials and Small Peptides.综述：乳腺癌 HER2 受体放射性核素分子成像的研究进展——聚焦进入临床试验和应用的分子探针和小肽
Molecules. 2021 Oct 27;26(21):6482. doi: 10.3390/molecules26216482.
7
A systematic review of dual targeting in HER2-positive breast cancer.HER2 阳性乳腺癌的双重靶向治疗系统评价。
Cancer Treat Rev. 2014 Mar;40(2):259-70. doi: 10.1016/j.ctrv.2013.09.002. Epub 2013 Sep 11.
8
Human epidermal growth factor receptor 2-targeted therapies in breast cancer.人表皮生长因子受体 2 靶向治疗在乳腺癌中的应用。
Expert Opin Biol Ther. 2013 Jul;13(7):949-52. doi: 10.1517/14712598.2013.789497. Epub 2013 Apr 9.
9
HER2 aberrations in cancer: implications for therapy.HER2 基因异常与癌症：对治疗的影响。
Cancer Treat Rev. 2014 Jul;40(6):770-80. doi: 10.1016/j.ctrv.2014.02.008. Epub 2014 Mar 12.
10
From bench to bedside: What do we know about hormone receptor-positive and human epidermal growth factor receptor 2-positive breast cancer?从实验室到临床：我们对激素受体阳性和人表皮生长因子受体2阳性乳腺癌了解多少？
J Steroid Biochem Mol Biol. 2015 Sep;153:45-53. doi: 10.1016/j.jsbmb.2015.05.005. Epub 2015 May 18.

本文引用的文献

1
Detection of HER2 expression using Tc-NM-02 nanobody in patients with breast cancer: a non-randomized, non-blinded clinical trial.使用 Tc-NM-02 纳米抗体检测乳腺癌患者的 HER2 表达：一项非随机、非盲的临床试验。
Breast Cancer Res. 2024 Mar 8;26(1):40. doi: 10.1186/s13058-024-01803-y.
2
Tc‑labeled single-domain antibody for SPECT/CT assessment of HER2 expression in diverse cancer types.Tc 标记的单域抗体用于 SPECT/CT 评估多种癌症类型的 HER2 表达。
Eur J Nucl Med Mol Imaging. 2023 Mar;50(4):1005-1013. doi: 10.1007/s00259-022-06066-3. Epub 2022 Dec 9.
3
An overview of resistance to Human epidermal growth factor receptor 2 (Her2) targeted therapies in breast cancer.乳腺癌中对人表皮生长因子受体2（Her2）靶向治疗的耐药性概述。
Cancer Drug Resist. 2022 Jun 1;5(2):472-486. doi: 10.20517/cdr.2022.09. eCollection 2022.
4
Pre-Clinical Study of the [F]AlF-Labeled HER2 Affibody for Non-Invasive HER2 Detection in Gastric Cancer.用于胃癌中HER2非侵入性检测的[F]AlF标记HER2亲和体的临床前研究
Front Med (Lausanne). 2022 Feb 16;9:803005. doi: 10.3389/fmed.2022.803005. eCollection 2022.
5
Breast Cancer-Epidemiology, Risk Factors, Classification, Prognostic Markers, and Current Treatment Strategies-An Updated Review.乳腺癌——流行病学、危险因素、分类、预后标志物及当前治疗策略——最新综述
Cancers (Basel). 2021 Aug 25;13(17):4287. doi: 10.3390/cancers13174287.
6
Development of a Tc-Labeled Single-Domain Antibody for SPECT/CT Assessment of HER2 Expression in Breast Cancer.Tc 标记单域抗体用于 SPECT/CT 评估乳腺癌中 HER2 表达的研究
Mol Pharm. 2021 Sep 6;18(9):3616-3622. doi: 10.1021/acs.molpharmaceut.1c00569. Epub 2021 Jul 30.
7
Radiolabeled nanobodies for tumor targeting: From bioengineering to imaging and therapy.放射性标记纳米抗体用于肿瘤靶向：从生物工程到成像和治疗。
Biochim Biophys Acta Rev Cancer. 2021 Apr;1875(2):188529. doi: 10.1016/j.bbcan.2021.188529. Epub 2021 Feb 27.
8
[The Breast Cancer Cohort Study in Chinese Women: research design and preliminary results of clinical multi-center cohort].中国女性乳腺癌队列研究：临床多中心队列的研究设计与初步结果
Zhonghua Liu Xing Bing Xue Za Zhi. 2020 Dec 10;41(12):2046-2052. doi: 10.3760/cma.j.cn112338-20200507-00694.
9
Targeting and imaging of HER2 overexpression tumor with a new peptide-based Ga-PET radiotracer.新型基于肽的 Ga-PET 放射性示踪剂用于 HER2 过表达肿瘤的靶向和成像。
Bioorg Chem. 2021 Jan;106:104474. doi: 10.1016/j.bioorg.2020.104474. Epub 2020 Nov 13.
10
HER2-directed antibodies, affibodies and nanobodies as drug-delivery vehicles in breast cancer with a specific focus on radioimmunotherapy and radioimmunoimaging.曲妥珠单抗、亲和体和纳米抗体作为药物载体在乳腺癌中的应用，特别关注放射免疫治疗和放射免疫显像。
Eur J Nucl Med Mol Imaging. 2021 May;48(5):1371-1389. doi: 10.1007/s00259-020-05094-1. Epub 2020 Nov 12.

针对乳腺癌的 HER2 靶向小分子探针的临床前研究进展。

Preclinical research progress in HER2-targeted small-molecule probes for breast cancer.

机构信息

Department of Medical Imaging, Shanxi Medical University, 030001, Taiyuan, China.

Third Hospital of Shanxi Medical University, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences Tongji Shanxi Hospital, 030032, Taiyuan, China.

出版信息

Radiologie (Heidelb). 2024 Nov;64(Suppl 1):47-53. doi: 10.1007/s00117-024-01338-5. Epub 2024 Jul 22.

DOI:10.1007/s00117-024-01338-5
PMID:39039211
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11602795/
Abstract

Breast cancer is a malignant tumor that has the highest morbidity and mortality in women worldwide. Human epidermal growth factor receptor 2 (HER2) is a key driver of breast cancer development. Therefore, accurate assessment of HER2 expression in cancer patients and timely initiation or termination of anti-HER2 treatment are crucial for the prognosis of breast cancer patients. The emergence of radiolabeled molecular probes targeting HER2 makes this assessment possible. This article describes different types of small-molecule probes that target HER2 and are used in current preclinical applications and summarizes their advantages and disadvantages.

摘要

乳腺癌是一种恶性肿瘤，在全球范围内女性的发病率和死亡率最高。人表皮生长因子受体 2（HER2）是乳腺癌发展的关键驱动因素。因此，准确评估癌症患者的 HER2 表达水平，并及时开始或停止抗 HER2 治疗，对乳腺癌患者的预后至关重要。针对 HER2 的放射性标记分子探针的出现使得这一评估成为可能。本文描述了目前应用于临床前研究的不同类型针对 HER2 的小分子探针，并总结了它们的优缺点。